EBITDA Margin % is calculated as EBITDA divided by its Revenue. Apex Healthcare Bhd's EBITDA for the
three
months ended in Sep. 2025 was RM27.9 Mil. Apex Healthcare Bhd's Revenue for the
three
months ended in Sep. 2025 was RM253.0 Mil. Therefore, Apex Healthcare Bhd's EBITDA margin for the quarter that ended in Sep. 2025 was 11.04%.
Apex Healthcare Bhd (XKLS:7090) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Apex Healthcare Bhd EBITDA Margin % Related Terms
Apex Healthcare Bhd EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Apex Healthcare Bhd's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7090 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Apex Healthcare Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Healthcare Bhd EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Apex Healthcare Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Apex Healthcare Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Healthcare Bhd (XKLS:7090) has a EBITDA Margin % of 11.04% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apex Healthcare Bhd and its competitors. This is near median its historical median of 12.13. Over the past decade, Apex Healthcare Bhd's EBITDA Margin % has ranged from 9.53 to 47.21.
Is Apex Healthcare Bhd's EBITDA Margin % too high?
Apex Healthcare Bhd's current EBITDA Margin % of 11.04% is near median its 10-year median of 12.13. Over the past 10 years, this metric has ranged from a low of 9.53 to a high of 47.21. The Medical Distribution industry median EBITDA Margin % is 4.31. Apex Healthcare Bhd's value of 11.04% is 156.1% above this industry median. Overall, Apex Healthcare Bhd has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Apex Healthcare Bhd's EBITDA Margin % compare to MCK and COR?
Apex Healthcare Bhd's EBITDA Margin % of 11.04% can be compared against companies in the Medical Distribution industry. The industry median EBITDA Margin % is 4.31. Apex Healthcare Bhd's value of 11.04% is 156.1% above this benchmark. Historically, Apex Healthcare Bhd's own EBITDA Margin % has ranged from 9.53 to 47.21 over the past decade. While the company's 10-year median is 12.13 vs. the industry median of 4.31, Apex Healthcare Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Healthcare Bhd's current EBITDA Margin % of 11.04% is 156.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apex Healthcare Bhd and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Healthcare Bhd's current EBITDA Margin % is 11.04%, which is near median its own 10-year median of 12.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Healthcare Bhd stock overvalued right now?
Apex Healthcare Bhd (XKLS:7090) has a current EBITDA Margin % of 11.04%. The stock's GF Value™ is RM2.27, compared to a current price of RM2.61 — trading 15% above its estimated fair value. The current EBITDA Margin % is 11.04%, which is near median its 10-year median of 12.13 and 156.1% above the Medical Distribution industry median of 4.31. Apex Healthcare Bhd's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Apex Healthcare Bhd (XKLS:7090), the current EBITDA Margin % is 11.04% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Healthcare Bhd (XKLS:7090) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Healthcare Bhd stock appears to be overvalued.
The current stock price of RM2.61 is trading 15% above its estimated GF Value™ of RM2.27.
Key valuation signals for XKLS:7090:
EBITDA Margin %: 11.04% (near median its 10-year median of 12.13)
GF Value™: RM2.27 vs. price of RM2.61 (15% above fair value)
Industry Position: 156.1% above the Medical Distribution median
No single metric tells the full story. See the XKLS:7090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Healthcare Bhd is an investment holding company for a group of companies engaged in the development, manufacturing, marketing, and distribution of pharmaceuticals, diagnostics, consumer healthcare products, and orthopedic devices. It has direct operations in Malaysia, Singapore and Others. The company has two manufacturing plants in Melaka and Penang. It has three segments: Manufacturing, Distribution and Corporate. It derives maximum revenue from Malaysia and also has a presence in Singapore and other couintries.
63GF Score
Get the complete analysis for XKLS:7090
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7090 has been successfully added to your 
